Total Signatories & Supporters
Canadian
International
Concerned Citizens
Scientist/Researchers
Healthcare Professionals
Legal Professionals
Given the accumulating evidence of concern, on behalf of the Canadian public, we call on our Canadian government representatives and public health officials, for:
An immediate halt to the use of and a recall of the COVID-19 mRNA vaccine products.
An independent and transparent public inquiry into the regulatory processes leading to the approval of these products and their ongoing use.
Scientific assessments and analyses of all mRNA products to determine the health risks to humans from residual plasmid DNA, potential aberrant protein production, and shift to IgG4 antibodies.
Access to data and funding for independent research to assess the potential link between the COVID-19 mRNA vaccines and the recent probable increase in cancer rates and mortality,including any association with the SARS-CoV-2 virus itself.
Canadian researchers and professionals [in alphabetical order]:
Elizabeth Bastian, MDCM, GP in Oncology, Clinical Practitioner (retired)
Robert Béliveau MD, retraité
Jean Marc Benoit, MD, Emergency Physician, Pembroke Regional Hospital, Assistant Adjunct/Clinical Professor McMaster University
Carole Beveridge, MSc Integrated Health Care, BSc Phm, Consultant Pharmacist/ Deprescribing Advocate
Jo Ann Bowle-Evans, BA, MD, retired
Deborah Brakeley, MEd and RCC (Registered Clinical Counsellor)
Byram W. Bridle, PhD, Associate Professor of Immunology and Virology (specializing in vaccinology), Department of Pathobiology, University of Guelph
Alan Cassels, MPA, Independent pharmaceutical policy researcher and author, BC
Claudia Chaufan, MD, PhD, Associate Professor of Health Policy and Management, York University
Sarah Choujounian, former RPN
Matthew Cockle, PhD English, Independent Researcher and advocate for rights-based, democratic governance
Gail Davidson, retired lawyer, human rights activist, BC
Stefan Eberspaecher, DC
André Fortier, ostéopathe
George Gillson, MD, PhD, Functional Medicine/Functional Medicine Laboratory Testing Consultant
Mario Giroux, MD, Chirurgien orthopédiste
Natasha Gonek, BSc, NCIT Specialized – Investigator, Independent Researcher, Consultant
Dmitry O. Gorodnichy, PhD Computing Science, Data Scientist & 2024 PIPSC Vice-Presidential Candidate
L. Maria Gutschi, BSc Phm, PharmD, Pharmacy Consultant
Ondrej Halgas, PhD Biomedical Sciences, Independent Researcher
John Hardie, BDS, MSc(Path), PhD, FRCDC, Retired Oral Pathologist
Jennifer Hibberd, BSc, DDS, DPD, MRCDC, ROHP(t) Fellow of Independent Medical Alliance, CCCA & WCH–Founder,
CHA – VP
Roger Hodkinson, MA, MB, Bchir (Cantab), FRCPC, Retired Pathologist
Charles D. Hoffe, MD, Family Physician
York Hsiang, MB, ChB, MHSc, FRCSC, Professor Emeritus of Surgery, University of British Columbia
Niel A. Karrow, PhD Immunotoxicology, Professor, Department of Animal Biosciences, University of Guelph
Rochagné Kilian, MB.Ch.B, CCFP, CCFP EM, Co-Founder and President of K Wellness
David Kukke, Professional Firefighter (retired), Independent Researcher
Marian P. Laderoute, PhD Medical Sciences – Immunology, NCI expert witness on spike mRNA shedding, QC
Justine Lalonde, MD, psychiatre
René Lavigueur, Médecin de famille
Edward Leyton, BSc MD FCFP MDPAC(C), retired Adjunct Professor, Family Medicine, Queens University and Clinical Director, Integrative Medicine & Psychotherapy
Christian Linard, PhD, DEPD in Clinical Biochemistry, Full Professor, Université du Québec à Trois-Rivières
Thomas Maler, PhD, retired biochemist & molecular biologist from Sick Kids Hospital (Cystic Fibrosis and Tay-Sach’s disease expert), BC
Bonnie Mallard, PhD, Professor of Immunology & Immunogenetics, Department of Pathobiology, University of Guelph
Susan Beth Martin, RPh, BCGP, Consultant Pharmacist
Bernard Massie, PhD, Retired Researcher and former General Manager at the National Research Council of Canada Human Health Therapeutics Research Centre and Associate Professor of Microbiology and Immunology
Deanna McLeod, Principal of Research Firm Kaleidoscope Strategic
Lynda McLeod, BScN MALT CPCC, former Registered Nurse Educator
Joanne Mulhall, CCIr, NNCP, Certified Nutritionist
Kanji Nakatsu, PhD, Professor Emeritus – Pharmacology, Queen’s University
Susan E. Natsheh, MD, retired
Julian G.B. Northey, MSc, PhD, Former Adjunct Professor Molecular Genetics & Bioinformatics, Ontario Tech University; Quantum Physics Innovator; President & CSO of Frontier Agri-Science Inc.
Phil Oldfield, DPhil, Retired Clinical Biochemist
Michael Palmer, MD, former professor of biochemistry
Eric Payne, MD, MPH, FRCPC, Pediatric Neurologist, Clinical Assistant Professor of Pediatrics & Neurosciences
Steven Pelech, PhD, Professor of Medicine, University of British Columbia
Michel Pelletier, ND du Collège des Naturopathes du Québec (CNQ)
Christopher Pinto, MD
Patrick Provost, PhD, Expert in RNA & lipid nanoparticles, Full Professor (retired), Université Laval
Chantal Raymond, éducatrice
Wendi Roscoe, MSc, PhD, RHN (registered holistic nutritionist), Natural Clinical Practitioner
Jessica Rose, BSc, MSc, PhD, Fellow at Brownstone Institute and Independent Medical Alliance
Simon Ruelland, Médecin de famille
Christopher A. Shaw, PhD, Professor, Department of Ophthalmology & Visual Sciences, University of British Columbia
Christopher Shoemaker, MD CCFP, NCI expert witness on child mRNA injuries, ON
David J. Speicher, PhD DTM, Virologist, Cyrus Scientific Inc.
Liam Sturgess, Secretary of the Canadian Citizens’ Hearing (2022), Independent Researcher
Mark Trozzi, MD, World Council of Health, World Council of Health Canada, DrTrozzi.news
Mariko Uda, BSc Biology & Chemistry, BASc & PhD Engineering, Independent Researcher
Regina Watteel, PhD Statistics, Independent Researcher
International researchers and professionals [in alphabetical order]:
AUSTRALIA
Ian Brighthope, Professor, MB BS FACNEM FACHM DipAgSci, Director of Nutritional and Environmental Medicine, National Institute of Integrative Medicine
Robyn Cosford, MBBS(Hons), FACNEM FASLM, Professor and Chair, CHD Australia Chapter
Julian Fidge, BPharm, Grad Dip App Sc (Comp Sc), MBBS, FRACGP, MMed (Pain Management), Practice Principal & Director, South Wangaratta Medical Centre
Julian Gillespie, LLB, BJuris, former barrister
Jeyanthi Kunadhasan, Anaesthetist and Perioperative Physician, MD (UKM), MMed (AnaesUM), FANZCA , MMED (Monash), Independent Researcher
Andrew McIntyre, MBBS FRACP, Gastroenterologist
Christopher Neil, MBBS FRACP, PhD, President, Australian Medical Professionals Society
Geoffrey Norman Pain, PhD BSc(Hons), Endotoxin Specialist Consultant
Peter Parry, MBBS, PhD, FRANZCP, Cert Child & Adol Psychiatry, A/Prof, University of Queensland
Duncan Syme, MBBS FRACGP DROCG, Vice President, Australian Medical Professional Society
FRANCE
Hélène Banoun, PhD, Pharmacist, INSERM, retired, Independent Researcher
GERMANY
Christof Plothe, DO, World Council for Health
SWEDEN
Jonathan D. Gilthorpe, BSc (Hons), PhD, Docent, Associate Professor, Umeå University
UK
Sonia Elijah, BSc, Investigative Journalist
Tess Lawrie, MBBCh, PhD, World Council for Health
USA
Dr. Eleftherios Gkioulekas, Professor of Mathematics and Statistical Sciences, Undergraduate Program Coordinator, University of Texas Rio Grande Valley
Nicolas Hulscher, MPH, Epidemiologist and Administrator, The McCullough Foundation
Brook Jackson, Pfizer Whistleblower
Amy W. Kelly, Program Manager of the WarRoom/DailyClout Pfizer Documents Analysis Project, Co-Editor and Independent Researcher, DailyClout
Pierre Kory, MD, MPA, Specialist in Internal Medicine, Pulmonary Diseases, and Critical Care Medicine; Co-Founder, Leading Edge Clinic; President and Co-Founder Emeritus, FLCCC Alliance; Chief Scientific Advisor, Rebuild Medicine
Kevin McKernan, BSc, CSO/Founder, Medicinal Genomics
Mark Nathaniel Mead, MSc, PhD, Epidemiologist & Science Editor, Research Associate, The McCullough Foundation
David Shaw, Independent Researcher and Writer/Co-author of The Pfizer Papers, WarRoom/DailyClout Pfizer Documents Analysis Project
Linnea Wahl, MS, Retired Health Physicist, WarRoom/DailyClout Pfizer Documents Analysis Project
David M. Wiseman, PhD, MR PharmS, Research Scientist
The Call to Halt-19 Letter was emailed to the following ~1,200 prov./territ. & federal representatives and health officials along with a cover letter in 2025. Was it sent to your representatives?
The brochure may be printed without alteration on 8.5″ x 11″ paper double-sided flipped on short-edge.
call2halt19_brochure_27aug2026 (version 2 – updated)
call2halt19_brochure_26mar2026 (version 1 – old)
Folding instructions:
Canadian scientists, clinicians, and other professionals have reached out to Canadian authorities for reassessment of the COVID-19 mRNA vaccines. However, our concerns have not been addressed and continue to compound. Our letter focuses on the Canadian context and will be shared with Canadian government and public health officials.
We are calling for a halt to the use of COVID-19 mRNA vaccines in Canada, a public inquiry into their approval and ongoing use, and much needed assessment and research of emerging safety concerns. We are particularly aware of the numerous Canadians who have been injured following receipt of a COVID-19 mRNA vaccine. There is an urgent need for research into the potential mechanisms of harm so that there can be improved diagnosis, treatment and support.
Inspired by the North Group letter, Canadian scientists and clinicians authored this letter with the support of the Canadian Citizens Care Alliance and RéInfo Québec.
The letter has been/will be sent to Canadian government representatives and public health officials, including but not limited to the following: members of federal and provincial/territorial parliaments and legislatures including every federal party leader and every premier; senators; Public Health Agency of Canada (PHAC), Health Canada, National Advisory Committee on Immunization (NACI); and the chief medical officers of each province.
We require this information to validate people signing in support of this letter and for statistical purposes.
An ATIP is an Access to Information and Privacy request (often referred to as a Freedom of Information request) that anyone in Canada can make to any Canadian federal agency (link). Most government information is available through ATIP requests, including internal documents and communications. ATIPs revealed internal communications of Health Canada scientists regarding their observations about the emerging issues surrounding the COVID-19 mRNA vaccines and are referenced in our letter.
Yes, there are a number of concerns such as inadequate testing, lack of efficacy, and serious adverse events. For a summary of concerns related to the Pfizer/BioNTech vaccine, we refer the reader to this article by Oldfield et al. (2024).
Messenger Ribonucleic Acid (mRNA) is a copy of genetic sequences contained in a segment of DNA (a gene), and is used to make proteins. It is created within the cell’s nucleus from a gene in a process called transcription, and is then transferred to the ribosomes located in the cell’s cytoplasm where it is read (translated) to make proteins. Nucleotides are the building blocks of DNA and mRNA. The order of the nucleotides in mRNA directs the types of amino acids used to build proteins. In the case of the COVID-19 mRNA vaccines, mRNA is used to produce the spike protein of the SARS-CoV-2 virus.
Plasmids are circular DNA pieces found in bacteria and other small microorganisms that are separate from the organism’s chromosomal DNA. They replicate along with their host and may also be able to replicate independently. Plasmids are used by scientists as a tool to rapidly create large numbers of copies of desired DNA. For the COVID-19 mRNA vaccine products, spike protein DNA was inserted into plasmids, which were then placed into E. coli bacteria, chosen because of their ability to replicate rapidly. This created the vast amounts of DNA used to generate the mRNA required for the rapid roll-out of the mRNA COVID-19 vaccines. In this way, plasmids had a major presence in the mass production of the mRNA vaccines. Further details about this process are available at Palmer & Gilthorpe (2023).
Lipid nanoparticles (LNPs) are made of biosynthetic fat molecules that self-assemble into small spherical structures that can contain modified mRNA inside. They can act like spherical envelopes that deliver mRNA through the circulation to the cells, protecting the mRNA from degradation and facilitating its entry into cells by fusing with their outer membranes. Without encapsulation by the LNP, mRNA would be rapidly destroyed in the circulation and unable to serve as a template for the production of its protein product inside of cells. (reference: Nature Reviews Materials (2021))
The SV40 promoter-enhancer sequence is a segment of DNA that has been copied from Simian Virus 40 (SV40), a cancer-causing DNA virus that infects monkeys and humans.
The promoter-enhancer sequence is important for the production of RNA from DNA (transcription). Promoters are DNA sequences that signal where transcription is to start, while enhancer sequences increase the rate of gene transcription. In the laboratory, scientists use the SV40 promoter-enhancer sequence to increase production of RNA for a specific gene for scientific study (a gene is a segment of DNA that contains instructions for making a specific protein).
The SV40 promoter-enhancer sequence is also used by scientists in gene therapy to promote transport of DNA fragments into the cell’s nucleus and integration of DNA into the genome. (Oldfield et al. (2024))
The use of SV40 sequences by Pfizer/BioNTech for the production of the COVID-19 mRNA products was not disclosed to regulators. As this SV40 sequence functions in mammalian cells, it has potential to impact human cellular functions. The genetic implications upon humans from the presence of the SV40 promoter-enhancer sequence are not known.
mRNA is made of sequences of various nucleotides. The order of these nucleotides in triplets provides the instructions for the synthesis of proteins. Proteins are made of chains of amino acids. The mRNA’s nucleotides are read in groups of three to instruct the order in which the amino acids are to be added to create a particular protein. However, the synthetic N1-methylpseudouridine nucleotide used in the COVID-19 mRNA vaccines are slippery and may be skipped when the mRNA is read by ribosomes. This will change the sequence of amino acids in the resulting protein. Even one small error in protein production may have a significant impact on the final protein and its interactions within the human body. This skipping of nucleotides during the process of reading the mRNA (translation) is called ribosomal frameshifting. These errors have unknown consequences on human health, including autoimmune and prion diseases. (reference: Oldfield et al. (2024))
IgG4 is a specific type of antibody, also known as an immunoglobulin. Humans have 5 classes of immunoglobulins: IgA, IgM, IgD, IgE and IgG. IgG is the most abundant type of antibody in blood and is found in all bodily fluids. It may enter organs and is the primary type of antibody to cross the placenta.
There are 4 subclasses of IgG antibodies – 1 to 4. Normally, IgG4 is the least abundant subclass. However, scientists have found that with repeated COVID-19 mRNA injections, IgG levels shift to make relatively more IgG4 antibodies. IgG4 is not efficient at generating an immune response against infections and may even block them, making one more likely to develop an infection. Another concern is that higher IgG4 levels have been found to be associated with a group of autoimmune illnesses known as IgG4-related diseases. For more information, see World Council for Health (2025).
Many viruses have links to causing cancer. Research indicates this to also be true for SARS-CoV-2, the virus that causes COVID-19 illness (Basaran et al. (2025)). In particular, the spike protein damages DNA and the virus impairs DNA repair.
Scientists have also identified a number of plausible mechanisms that would increase one’s risk of developing cancer following a COVID-19 mRNA injection. Residual DNA from the production process has been found in both the Pfizer/BioNTech and Moderna COVID-19 products. This DNA is contained within the lipid nanoparticles (LNPs), and thus has the potential to enter the cell’s cytoplasm. Free DNA in the cytoplasm is a risk for cancer development. Also, this DNA may be incorporated into the cell’s nucleus during the period of cell division. Inside the nucleus it has the potential for integration into the genome with unknown health impacts.
Furthermore, the Pfizer/BioNTech COVID-19 products have been found to contain the SV40 promoter-enhancer sequence. This is a gene-therapy tool which is used by scientists to import DNA into the nucleus, even when it is not dividing. It enhances the likelihood for foreign DNA to be integrated into the genome with potential to cause gene mutations. It can also bind to and impair the function of the p53 tumour suppressor gene, which plays an important role in preventing the replication of cancer genes. The COVID-19 mRNA products may also impair cancer surveillance in other ways (Seneff et al. (2022)).
Since the COVID-19 mRNA products underwent approval through a vaccine regulatory process, their potential to cause cancer or gene mutations was not part of the clinical or pre-clinical trials. The impact of these contaminants on human health is not known.
To learn more about these organizations, visit their websites: CCCA, Réinfo Québec
Our initiative is non-partisan. We invite anyone from any political affiliation to sign our letter and use our letter to help bring about needed change. In fact, we hope all political parties will pick up this issue.
